Haleon (HLN) Other Non-Current Liabilities (2021 - 2026)
Haleon's (HLN) quarterly Other Non-Current Liabilities came in at -$52.3 million in Q2 2026, down 30.18% on a QoQ basis from -$40.2 million in Q4 2025.
Haleon (HLN) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Haleon (HLN) has 6 years of Other Non-Current Liabilities data on file, last reported at -$52.3 million in Q2 2026.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to -$52.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$52.3 million (changed N/A YoY) and the FY2025 annual result came in at -$39.9 million, down 154.77% from the prior year.
- Other Non-Current Liabilities slipped to -$52.3 million in Q2 2026, from -$40.2 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $73.2 million in Q4 2024 to a low of -$83.1 million in Q2 2022.
- A 5-year average of -$8.5 million and a median of -$30.8 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities jumped 115.7% — and 2025, when it tumbled 154.94%.
- Tracing HLN's Other Non-Current Liabilities over 5 years: stood at $30.5 million in 2022, then surged by 115.7% to $65.8 million in 2023, then rose by 11.22% to $73.2 million in 2024, then plunged by 154.94% to -$40.2 million in 2025, then plunged by 30.18% to -$52.3 million in 2026.
- The last three Other Non-Current Liabilities figures came in at -$52.3 million (Q2 2026), -$40.2 million (Q4 2025), and $73.2 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.09 Bn | 7.43 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.33 Mn |
| Dec 31, 2025 | -40.19 Mn |
| Dec 31, 2024 | 73.16 Mn |
| Jun 30, 2024 | -34.08 Mn |
| Dec 31, 2023 | 65.78 Mn |
| Jun 30, 2023 | -27.53 Mn |
| Dec 31, 2022 | 30.50 Mn |
| Jun 30, 2022 | -83.11 Mn |
| Dec 31, 2021 | 36.40 Mn |